Apitegromab (SRK-015)
Spinal Muscular Atrophy (Types 2 & 3)
Key Facts
About Scholar Rock
Scholar Rock is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies for serious diseases by targeting protein growth factors in their latent, inactive state. Its most advanced asset, apitegromab, has shown promising Phase 3 results in spinal muscular atrophy (SMA) and is being evaluated in cardiometabolic disorders. The company's strategy leverages its unique scientific platform to build a pipeline across multiple therapeutic areas with high unmet need, positioning it for potential near-term commercialization and long-term growth.
View full company profileAbout Scholar Rock
Scholar Rock is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies for serious diseases by targeting protein growth factors in their latent, inactive state. Its most advanced asset, apitegromab, has shown promising Phase 3 results in spinal muscular atrophy (SMA) and is being evaluated in cardiometabolic disorders. The company's strategy leverages its unique scientific platform to build a pipeline across multiple therapeutic areas with high unmet need, positioning it for potential near-term commercialization and long-term growth.
View full company profileTherapeutic Areas
Other Spinal Muscular Atrophy (Types 2 & 3) Drugs
| Drug | Company | Phase |
|---|---|---|
| Apitegromab | Scholar Rock Holding | Phase 3 |